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Abstract
The dynamic addition and removal of covalent posttranslational modifications (PTMs) on histone 
proteins serves as a major mechanism regulating chromatin-templated biological processes in 
eukaryotic genomes. Histone PTMs and their combinations function by directly altering the 
physical structure of chromatin and as rheostats for effector protein interactions. In this chapter, 
we detail microarray-based methods for analyzing the substrate specificity of lysine 
methyltransferase and demethylase enzymes on immobilized synthetic histone peptides. 
Consistent with the “histone code” hypothesis, we reveal a strong influenceof adjacent 
and,surprisingly,distant histonePTMs onthe ability of histone-modifying enzymes to methylate or 
demethylate their substrates. This platform will greatly facilitate future investigations into histone 
substrate specificity and mechanisms of PTM signaling that regulate the catalytic properties of 
histone-modifying enzymes.
1. INTRODUCTION
Eukaryotic genomes are tightly packaged in cell nuclei by their ability to associate with 
histone proteins. These histone-DNA complexes are first organized into nucleosomes, which 
are further folded into higher-order chromatin fibers that are poorly understood 
(Khorasanizadeh, 2004; Kornberg & Lorch, 1999; Luger, Mader, Richmond, Sargent, & 
Richmond, 1997). A major focus of modern biomedical research has been to understand 
how genetic information is accessed in the context of chromatin to control DNA-templated 
processes like gene transcription, replication, and repair, and how deregulation of these 
processes contributes to the initiation and progression of human disease (Detrich, 1986; 
Maze, Noh, & Allis, 2013; Portela & Esteller, 2010).
Posttranslational modifications (PTMs) on histone proteins have emerged as key epigenetic 
regulators of genome accessibility and function (Kouzarides, 2007). Fundamental 
breakthroughs in our understanding of chromatin regulation have been made through the 
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identification of protein machineries that add (write), remove (erase), and bind (read) these 
marks (Rothbart & Strahl, 2014). Fueled by technological advances in mass spectrometry-
based proteomics, more than 20 unique histone PTMs have been identified at upward of 80 
different histone residues, many of which cluster in the unstructured N- and C-terminal tail 
domains that protrude from the nucleosome core (Huang, Sabari, Garcia, Allis, & Zhao, 
2014; Zhao & Garcia, 2015).
In 2000, the concept of a “histone code” emerged as a hypothesis to stimulate new thinking 
about how histone PTMs might function in a combinatorial manner to dynamically regulate 
chromatin interactions of histone reader proteins (Strahl & Allis, 2000). In addition, it was 
postulated that much like histone PTM readers, the enzymes that write and erase these marks 
would themselves be influenced by preexisting PTM patterns. While significant effort has 
been placed on identifying and characterizing enzymes and effector proteins responsible for 
writing, erasing, and reading histone marks (Fig. 1), deciphering regulatory mechanisms of 
combinatorial PTM patterning has proven challenging, due in part to the sheer complexity of 
the histone PTM landscape.
To address this issue, we developed a high-density histone peptide microarray platform to 
enable rapid and high-throughput biochemical characterization of histone PTM-specific 
antibodies and readers in the context of complex histone PTM patterns (Fuchs, Krajewski, 
Baker, Miller, & Strahl, 2011; Rothbart et al., 2015; Rothbart, Krajewski, Strahl, & Fuchs, 
2012). Briefly, synthetic biotinylated peptides, posttranslationally modified with up to eight 
physiologically relevant combinations of lysine acetylation and methylation (mono-, di-, and 
trimethyl), arginine methylation (mono, symmetric dimethyl, and asymmetric dimethyl) and 
citrullination, and serine/threonine phosphorylation, are deposited on streptavidin-coated 
glass slides that can then be used to examine aspects of protein function like binding and 
enzymatic activity.
Methods for the synthesis of combinatorially modified biotinylated histone peptides, 
microarray fabrication using these peptides, and the characterization of histone readers and 
antibodies with histone peptide microarrays were previously described (Rothbart et al., 
2012). In this chapter, we now detail the utility of this same peptide microarray platform, 
which is commercially available through Epicypher and Millipore, for high-throughput 
substrate specificity profiling of histone lysine methyltransferases (KMTs) and demethylases 
(KDMs). We further reveal the influence of neighboring, and surprisingly distant, PTMs on 
the catalytic properties of histone-modifying enzymes.
2. ASSAY OPTIMIZATION
2.1 Design of Custom Print Formats
A number of variables should be considered when designing an enzyme assay for 
microarray screening. For instance, incubation times and enzyme concentrations that have 
been optimized for solution-based assays may not translate to a microarray format, 
particularly since substrate concentrations of an immobilized peptide or protein can be 
limiting by several orders of magnitude. To optimize assay conditions, including variables of 
time, buffer composition, enzyme concentration, and detection reagent, we used our recently 
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developed open source software package, ArrayNinja (see chapter “ArrayNinja: An Open 
Source Platform for Unified Planning and Analysis of Microarray Experiments” by Dickson 
et al.). ArrayNinja unifies the planning and analysis of microarray experiments to facilitate 
streamlined microarray customization and data processing. Shown in Fig. 2A is a format we 
have found useful for enzyme assay optimization that partitions 48 subarrays on a single 
slide by hydrophobic wax. Detailed procedures for wax deposition using a stamping device 
are described elsewhere (Partyka, Wang, Zhao, Cao, & Haab, 2014). These wax boundaries 
produce a well around each subarray of 64 unique features (275 μm spot diameter and 100 
μm between spots) and allows for hybridization of 6 μL reaction volumes. Representative 
slides for the optimization of a KMT assay with G9a are shown, where we were able to test 
seven enzyme concentrations and three detection antibodies (ie, antibodies that recognize the 
orders of H3K9 methylation that are generated by G9a), all in duplicate, on a single slide 
(Fig. 2B).
2.2 Detection Reagent Considerations
A critical optimization step when designing an assay for histone-modifying enzyme activity 
on microarrays is determining how catalysis will be monitored. Detection strategies most 
successful in our hands have relied on radioisotope incorporation or histone PTM-specific 
antibodies. Advantages and disadvantages of both radioisotopic and antibody readout of 
enzyme function are discussed in Sections 2.2.1 and 2.2.2, and methods for performing these 
assays are described in Section 3.
2.2.1 Radioisotopes—The activity of enzymes that write histone PTMs, including 
methyltransferases, acetyltransferases, and kinases can be monitored on microarrays by 
radioisotope incorporation. The use of radioisotopes for profiling the substrate specificity of 
the enzymes responsible for erasing histone PTMs presents a significant technical challenge 
for microarray analysis, as this would require the tedious synthesis of large peptide libraries 
that contain these isotopes. Radioactivity assays are advantageous when substrate specificity 
is unknown, and with enough chemical diversity in a substrate library, can be informative in 
identifying the target residue. However, the degree or order of modification (eg, mono-, di-, 
or trimethylation on lysine residues) cannot be defined with this detection strategy. Use of 
radioisotopes also enables a clear assessment of the influence neighboring PTMs have on 
enzymatic activity, since these direct labeling strategies are not confounded by the influence 
of PTMs on antibody-epitope recognition (Rothbart et al., 2015).
A major drawback of radioactivity assays, specifically methyltransferase and 
acetyltransferase assays, is the time required to collect data from an experiment. Tritium 
and 14C are low-energy beta emitters, requiring upward of 1 month exposure time to X-ray 
film to visualize results. Autoradiography enhancing reagents do not appear to be 
compatible with this array format. While it may be possible to decrease exposure times with 
the aid of phosphor screens, this has not been empirically tested. Kinases are more amenable 
to radioisotope-based microarray assays, as they rely on the use of the high-energy beta 
emitter [γ-33P] ATP as a cofactor (Rothbart et al., 2012), which is detectable by 
autoradiography following a brief exposure.
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2.2.2 Antibodies—Histone PTM-specific antibodies are widely used chromatin 
biochemistry tools, and more than 1000 commercial antibodies are available that recognize 
the diverse modification states on histone proteins. There are a number of advantages to 
using antibodies as detection reagents for histone-modifying enzymes on microarrays. 
Unlike radioisotopic readouts, antibody detection methods enable site-specific analysis of a 
particular substrate residue of interest and can discriminate between the various states of 
methylation found on histones. In addition, a number of pan PTM antibody reagents have 
been developed, many of which react well with the intended modifications on histones (data 
not shown). However, a number of these pan reagents show epitope specificity problems, 
albeit less strict than conventional antibodies, resulting in unequal discrimination among 
PTMs when presented in diverse sequence contexts. Antibody hybridization procedures are 
straightforward, require little material, do not generate radioactive waste, and can be 
detected within several hours.
A significant caveat to using antibodies as detection reagents is the influence, both positive 
and negative, of neighboring PTMs. Inclusion of control detection experiments in the 
absence of modifying enzyme or cofactor can help assess the behavior of the antibody being 
used. In addition, we recently characterized the specificity of over 100 commercially 
available histone PTM antibodies by microarray, and we created a publicfacing web portal, 
the Histone Antibody Specificity Database (www.histoneantibodies.com) (Rothbart et al., 
2015). This online resource is a useful tool for aiding in the selection of antibodies suitable 
for enzyme profiling experiments.
3. ASSAY METHODOLOGY
Later we detail methods for assaying the methyltransferase activity of G9a and the 
demethylase activity of JMJD2A–both enzymes that write and erase H3K9 methylation, 
respectively–on our previously described peptide microarray platform (Rothbart et al., 
2012). This print format benefits from the ability to assay >250 unique peptide substrates in 
a single assay. In addition, two identical subarrays are printed on each slide and can be 
separated by a silicon adhesive seal (eg, Epicypher #11-3001), by hydrophobic wax 
deposited with a slide imprinter (eg, Gel Company #WSP48-1), or by a PAP pen (eg, Sigma 
#Z377821). Subarray separation is useful for comparison of multiple conditions on the slide. 
For example, we commonly incubate the array in the absence or presence of enzyme on the 
same slide prior to antibody hybridization. We detail an antibody-based detection procedure, 
applicable to both classes of enzymes, and we also describe radioisotopic assays using the 
cofactor adenosyl-L-methionine, S-[methyl-3H] (3H-SAM) for histone methyltransferase 
assays on microarrays and in solution.
3.1 Microarray-Based Lysine Methyltransferase (KMT) Assays with G9a
Equipment and reagents
1. Tris–HCl, pH 8.8
2. MgCl2
3. Recombinant human G9a, amino acids 913-1210 (Epicypher #15-1008)
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4. S-adenosyl methionine (SAM)
5. Dithiothreitol (DTT)
6. Cold PBS, pH 7.6
7. Powdered bovine serum albumin (BSA)
8. Tween-20
9. Nontreated four-well dish (such as Thermo Scientific #267061)
10. 25×60 mm cover slips
11. Biotinylated histone peptide microarray, custom printed as previously described 
(Rothbart et al., 2012), or commercially available through Epicypher (#11-2001) 
or Millipore (#16-671).
12. Humidified microarray incubation chamber (such as VWR#97000-384).
Additional equipment and reagents specific to antibody detection
1. Histone PTM-specific primary antibody.
2. Fluorescent-labeled secondary antibody (such as Alexa Fluor® 647-conjugated 
anti-rabbit (Thermo #A-21244) or anti-mouse (Thermo #A-21235)).
3. Microarray scanner capable of scanning at ≤25 μm and equipped with lasers 
compatible with your secondary antibody conjugates.
Additional equipment and reagents specific to radioisotope detection
1. 3H-SAM (Perkin Elmer NET155001MC)
2. X-ray film
3. Film developer
General procedure
1. Equilibrate a microarray slide in KMT reaction buffer (50 mM Tris–HCl, pH 8.8, 
5 mM MgCl2, 4 mM DTT) for 10 min at room temperature.
2. Incubate the slide in a humidified microarray incubation chamber with 200 μL1 
KMT reaction buffer containing 1 μM enzyme2 and 60 μM SAM3 under a 
coverslip4 at 30°C for 2 h.
3. Wash the slide 2×5 min with PBS, pH 7.6 in the cold.
4. Dry the slide. We prefer a mini-centrifuge for this purpose, such as Sigma 
#Z674672. Alternatively, slides can be dried over a stream of filtered compressed 
air or by centrifugation in a 50-mL conical tube in a swinging-bucket rotor at 
800×g for 1 min.
1The volume requirement for a silicon adhesive seal is 350 and 500 μL for arrays separated by PAP pen.
2Enzyme concentration was optimized on 48-well slides at a range from 0 to 1 μM (Fig. 2B); 1 μM G9a was used for large-format 
arrays (Fig. 3A).
3For radioisotope assays, use 5 uCi 3H-SAM.
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5. Follow procedures below for detection with radioisotope or antibody.
Additional procedures and considerations for radioisotope detection
1. Step 3 above should be performed 5×5 min, and liquid waste should be discarded 
in accordance with your institution's radiation safety procedures.
2. For containment, the preferred drying method in step 4 above is centrifugation in 
a 50-mL conical tube.
3. Following step 4 above, expose the dry slide to X-ray film in an autoradiography 
cassette at −80°C for at least 1 month.
4. Bring the sealed autoradiography cassette to room temperature and process film 
through a developer.
Additional procedures and considerations for antibody detection
1. Prepare a dilution of primary antibody in hybridization buffer (PBS, pH 7.6, 5% 
BSA (w/v), 0.1% Tween-20). In general, begin with a dilution factor at the high 
end of the detection range by western blot.
2. Incubate the slide with 200 μL of diluted antibody under a coverslip for 1 h at 
4°C in a humidified microarray incubation chamber.
3. Remove the coverslip and wash 3×5 min with cold PBS.
4. Prepare a dilution of fluorescent secondary antibody (1:5000–1:10,000 for Alexa 
Fluor® 647) in hybridization buffer and incubate the slide for 30 min in the dark 
with gentle rotation at 4°C.
5. Wash the slide 3×5 min with PBS in the dark at 4°C.
6. Dip the slide 5× in 0.1× PBS to remove excess salt.
7. Dry the slide by centrifugation or compressed air as described earlier.
8. Scan the slide using a microarray scanner at ≥25 μm with a laser appropriate for 
your fluorescent secondary antibody.
9. Slides can be stored at 4°C protected from light for several days without 
appreciable loss of fluorescent signal.
3.2 Solution-Based KMT Assays with G9a
Equipment and reagents
1. Tris–HCl, pH 8.8
2. MgCl2
3. Recombinant human G9a, amino acids 913-1210 (Epicypher #15-1008)
4. DTT
5. 3H-SAM (Perkin Elmer #NET155001MC)
6. H3(1–20) peptide (Epicypher #12-0001)
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7. Trifluoroacetic acid (TFA)
8. NaHCO3, pH 9.0
9. P81 phosphocellulose filter paper (Whatman)
General procedure
1. Dilute G9a to a final concentration of 25 nM in KMT reaction buffer (50 mM 
Tris–HCl, pH 8.8, 5 mM MgCl2, 4 mM DTT) containing 0.5 μCi 3H-SAM.
2. Start reactions by addition of substrate peptide at a final concentration of 10 μM.
3. Quench reactions by addition of TFA to a final concentration of 0.5% (w/v).
4. Spot equal amounts of quenched reactions on P81 filter paper and dry at room 
temperature for 10 min.
5. Wash filter papers in a single beaker 4×5 min with 50 mM NaHCO3, pH 9.0.
6. Dry filter papers at room temperature for 20 min.
7. Place filter papers in scintillation vials and add an appropriate amount of 
scintillation fluid to submerge the paper.
8. Count tritium with a scintillation counter.
3.3 Microarray-Based Lysine Demethylase (KDM) Assays with JMJD2A
Equipment and reagents
1. HEPES, pH 7.5
2. NaCl
3. Recombinant human JMJD2A, amino acids 1–350 (Krishnan, Collazo, Ortiz-
Tello, & Trievel, 2012; see chapter “Purification, Biochemical Analysis, and 
Structure Determination of JmjC Lysine Demethylases” by Krishnan and 
Trievel)
4. (NH4)2Fe(SO4)2
5. L-Ascorbic acid
6. 2-OG
7. Cold PBS, pH 7.6
8. Powdered BSA
9. Tween-20
10. Nontreated four-well dish (such as Thermo Scientific #267061)
11. Biotinylated histone peptide microarray, custom printed as previously described 
(Rothbart et al., 2012) or commercially available through Epicypher (#11-2001) 
or Millipore (#16-671)
12. Humidified microarray incubation chamber (such as VWR#97000-384)
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13. Histone PTM-specific primary antibody
14. Fluorescent-labeled secondary antibody (such as Alexa Fluor® 647-conjugated 
anti-rabbit (Thermo #A-21244) or anti-mouse (Thermo #A-21235))
15. Microarray scanner capable of scanning at ≥25 μm and equipped with lasers 
compatible with your secondary antibody conjugates
General procedure
1. Equilibrate a microarray slide in KDM reaction buffer (50 mM HEPES, pH 7.5, 
50 mM NaCl, 50 μM (NH4)2Fe(SO4)2, 1 mM L-ascorbic acid, 1 mM 2-OG) for 
10 min at room temperature.
2. Incubate the slide in a humidified microarray incubation chamber with 500 μL 
KDM reaction buffer containing 0.313 μM enzyme5 at 25°C for 18 h.
3. Wash the slide 3×5 min with PBS, pH 7.6 in the cold.
4. Dry the slide. We prefer a mini-centrifuge for this purpose, such as Sigma 
#Z674672. Alternatively, slides can be dried by over a stream of filtered 
compressed air or by centrifugation in a 50-mL conical tube in a swinging-
bucket rotor at 800×g for 1 min.
5. Prepare a dilution of primary antibody in hybridization buffer (PBS, pH 7.6, 5% 
BSA (w/v), 0.1% Tween-20). In general, begin with a dilution factor at the high 
end of the detection range by western blot (1:1000–1:5000).
6. Incubate the slide with 500 μL of diluted antibody 1 h at 4°C in a humidified 
microarray incubation chamber.
7. Wash the slide 3×5 min with cold PBS.
8. Prepare a dilution of fluorescent secondary antibody (1:5000–1:10,000 for Alexa 
Fluor® 647) in hybridization buffer and incubate the slide for 30 min in the dark 
with gentle rotation at 4°C.
9. Wash the slide 3×5 min with PBS in the dark at 4°C.
10. Dip the slide 5× in 0.1× PBS to remove excess salt.
11. Dry the slide by centrifugation or compressed air as described earlier.
12. Scan the slide using a microarray scanner at ≤25 μm with a laser appropriate for 
your fluorescent secondary antibody.
13. Slides can be stored at 4°C protected from light for several days without 
appreciable loss of fluorescent signal.
5Enzyme concentration was optimized on 48-well slides at a range from 0 to 625 nM (Fig. 4A); 313 nM JMJD2A was used for large-
format arrays (Fig. 4B).
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4. ENZYME SPECIFICITY PROFILING BY MICROARRAY
Histone peptide microarrays have been a robust biochemical tool for the in vitro 
characterization of histone antibodies and readers in the context of complex histone PTM 
patterns (Fuchs et al., 2011; Rothbart et al., 2015, 2012). We therefore sought to expand the 
utility of this competitive assay platform for the interrogation of histone-modifying enzymes 
that act on peptide substrates. Here, we detail results obtained from successful screening of 
histone methyltransferase and demethylase activities using the methods described in Section 
3.
4.1 High-Throughput Profiling of G9a KMT Activity
Since the seminal discovery of the first histone lysine methyltransferase (Rea et al., 2000), 
and the link between site-specific histone methylation and gene transcription (Lee, Teyssier, 
Strahl, & Stallcup, 2005), much research has focused on the role of histone methylation 
signaling through chromatin in human health and disease (Greer & Shi, 2012). Notably, over 
50 known and predicted lysine methyltransferase enzymes have been identified (Petrossian 
& Clarke, 2011), many of which have histone substrates (Fig. 1). The lysine 
methyltransferase G9a (EKMT2/KMT1C) is a SET (Su(var)3-9-Enhancer of zeste-
Trithorax) domain-containing protein identified as the major enzyme responsible for 
catalysis of mono- and dimethylation on H3K9 (Collins et al., 2005; Tachibana, Sugimoto, 
Fukushima, & Shinkai, 2001). G9a activity through euchromatic H3K9 methylation has 
primarily been associated with gene silencing (Shankar et al., 2013). Several additional 
histone substrates of G9a have been identified, including H3K27 (Tachibana et al., 2001; Wu 
et al., 2011), H3K56 (Yu et al., 2012), and H1 (Tachibana et al., 2001; Trojer et al., 2009; 
Weiss et al., 2010). G9a also methylates a number of nonhistone proteins (Rathert et al., 
2008; West et al., 2010).
Using assay conditions optimized on 48-well microarrays (Fig. 2), we subjected G9a to 
methyltransferase assays on a large array format. This platform allows for simultaneous 
monitoring of enzymatic activity on over 250 unique substrates in a competitive assay 
format, yielding over 2000 specific catalytic measurements in a single experiment. 
Following incubation with G9a, we first detected new methylation of H3K9 with an 
H3K9me2-specific antibody (Fig. 3A). Antibody reactivity in the absence of G9a was 
screened as a control. Consistent with previous observations (Rothbart et al., 2015), 
reactivity of this antibody with H3K9me2-containing peptides was both positively and 
negatively impacted by neighboring modifications. As discussed earlier, this behavior of 
histone PTM-specific antibodies is a potential disadvantage of using these reagents to detect 
enzymatic activity (Fig. 3B). In particular, phosphorylation of H3S10 completely inhibited 
this antibody from recognizing H3K9me2. Based on this observation, H3S10p peptides were 
excluded from subsequent analysis following detection with this antibody to circumvent 
false-negative conclusions.
Another caveat of detecting the products of enzyme reactions on arrays with site-specific 
antibodies is the potential for missing substrates (ie, residues being methylated other than 
H3K9 would not be detected by the antibody). We therefore developed a procedure to screen 
for G9a activity by monitoring radioisotope incorporation using 3H-SAM as a cofactor (see 
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method above). The majority of peptides detected by the H3K9me2 antibody after G9a 
incubation also incorporated tritiated methyl groups (Fig. 3A), consistent with the 
conclusion that the preferential histone target of G9a is H3K9 (Collins et al., 2005; 
Tachibana et al., 2001). Notably, a number of distinct methylation substrates in the sequence 
context of H3(15–41) were detected by radioactivity, consistent with the observation that G9a 
can also methylate H3K27 in vitro (Tachibana et al., 2001; Wu et al., 2011). We were unable 
to detect H3K56 methylation by G9a on our array platform.
Analysis of quantified signal intensities from both antibody and radioisotope detection 
methods revealed new insights regarding the behavior of G9a catalytic activity toward H3K9 
in the presence of adjacent and distant histone PTMs (Fig. 3C). Modifications that enhanced 
and perturbed G9a activity toward H3(1–20) peptides were largely consistent between 
detection strategies. The unbiased nature of radioisotope incorporation allowed us to 
scrutinize the contribution of H3S10p to G9a activity, which, consistent with a previous 
observation (Rathert, Dhayalan, et al., 2008), was largely inhibited by this neighboring 
mark. In general, single PTMs toward the N-terminus of H3(1–20) inhibited G9a activity on 
H3K9, and PTMs toward the C-terminus of H3(1–20) enhanced G9a activity. In addition, 
several combinations of H3R2 modification (methylation and citrullination) with H3K4 
methylation enhanced G9a activity. These latter results were surprising, connecting distant 
PTMs and their combinations to G9a activity and function. Understanding how these long-
range PTMs contribute to G9a activity will be an exciting area of future study.
To validate the dynamics of combinatorial PTMs to G9a activity observed on microarrays, 
we performed in-solution filter-binding assays with 3H-SAM (Fig. 3D). The rate of methyl 
incorporation using H3(1–20) peptide substrates was determined to be linear over the course 
of 20 min, and no activity was measured on H3K9me3 peptides. Consistent with single time 
point measurements on the arrays and a previous observation (Rathert, Dhayalan, et al., 
2008), H3T6p completely inhibited G9a catalysis (Fig. 3D). In addition, we validated an 
enhancement of G9a activity on H3(1–20) peptides modified with asymmetric dimethylation 
at arginine 2 (H3R2me2a) in combination with H3K4me2. Furthermore, single in-solution 
filter-binding assay measurements along this linear scale for a number of other histone 
PTMs was consistent with the changes observed on the arrays (Fig. 3C and E). Collectively, 
these results demonstrate the utility of histone peptide microarrays in capturing the 
dynamics of histone methylation in the context of the “histone code,” and reveal 
combinatorial histone PTM patterns that may regulate the chromatin activity of G9a.
4.2 High-Throughput Profiling of JMJD2A KDM Activity
Methylation on lysine residues was long thought to be an irreversible modification until the 
discovery of the first lysine demethylase (KDM), LSD1 (lysine-specific demethylase 1), 
shown to remove mono- and dimethylation on histone H3K4 using its FAD-dependent amine 
oxidase activity (Shi et al., 2004). Since this landmark discovery, over 30 KDMs with 
activity specific for all of the major lysine methylation sites on histones have been identified 
(Fig. 1; Dimitrova, Turberfield, & Klose, 2015). This includes the discovery of an additional 
class of demethylase enzymes, the Jumonji demethylases, that coordinate iron and utilize α-
ketoglutarate (2-OG) as a cofactor (Tsukada et al., 2006). JMJD2A (KMD4A), a Jumonji 
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family KDM, was the first demethylase discovered to remove lysine trimethylation (Klose et 
al., 2006; Whetstine et al., 2006). JMJD2A is known to catalyze the removal of 
trimethylation at H3K9 and H3K36 and has been implicated in the regulation of gene 
expression, DNA damage signaling, DNA replication, and site-specific copy-number 
regulation (Black et al., 2013).
JMJD2A demethylase assays on histone peptide microarrays were first optimized using a 
48-well array (Fig. 2). Using a single optimization slide, we simultaneously detected signal 
with three different antibodies to the states of H3K9 methylation following hybridization 
with six concentrations of JMJD2A, all in duplicate (Fig. 4A). Consistent with previous 
reports (Tsukada et al., 2006), we show that H3K9me3 peptides are reduced to lower order 
methyl states (K9me2 and K9me1) in the presence of JMJD2A. The H3K9me2 antibody 
used for these experiments cross reacts with H3K36me2 (Rothbart et al., 2015), and we were 
able to observe demethylation of H3K36me3-containing peptides at the higher JMJD2A 
concentrations used in these optimization experiments (data not shown). In general, 
detecting reaction products was a more robust readout for enzyme activity than monitoring 
the disappearance of substrate (Fig. 4A). This is perhaps due to the high sensitivity of 
primary antibodies and the amplification provided by secondary antibody conjugation.
Using assay conditions optimized on the 48-well microarray, we performed JMJD2A 
demethylase assays on a large-format array. Following incubation with JMJD2A, we 
monitored the appearance of H3K9me1 by antibody detection (Fig. 4B). Antibody reactivity 
in the absence of JMJD2A was tested as a control. Analysis of quantified signal intensities 
from both JMJD2A treated and untreated arrays revealed JMJD2A is able to demethylate the 
majority of H3K9me3- and H3K9me2-containing peptides, whereas the H3K9me1-
containing peptides are not substrates (Fig. 4C). The H3K9me1 antibody used also cross-
reacted with H3K23me1 and monomethylation of lysines 5, 8, and 12 on the H4 tail, and 
none of these PTMs were substrates of JMJD2A (Fig. 4C).
We next sought to determine how neighboring PTMs influenced the catalysis of JMJD2A 
toward H3K9me2 and H3K9me3. As discussed earlier, the behavior of histone PTM 
antibodies (positive and negative) when presented with combinatorially modified PTM 
epitopes is a factor that must be considered when using these reagents for enzyme assay 
detection. The arrays used for these experiments displayed five combinatorially modified 
H3(1–20) peptides that also harbored all three methylation states at H3K9 (Fig. 4D). Focusing 
on these peptides allowed us to properly control for the behavior of the H3K9me1 antibody 
toward the product of JMJD2A demethylation in the context of neighboring PTMs. We saw 
little effect of H3 poly-acetylation or H3R8 dimethylation on the activity of JMJD2A toward 
H3K9me2 or H3K9me3 substrates. However, we show that like G9A (above), and consistent 
with a previous observation (Ng et al., 2007), JMJD2A activity on H3K9me2 and H3K9me3 
is blocked by neighboring H3S10 phosphorylation (Fig. 4D). These results demonstrate the 
utility of histone peptide microarrays for profiling the substrate specificity of KDMs and for 
deciphering the impact of the “histone code” on JMJD2A activity.
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5. SUMMARY AND PERSPECTIVES
Peptide microarrays have been a valuable tool for studying the influence of histone PTMs on 
antibody and reader protein recognition (Rothbart et al., 2012). The methods presented in 
this chapter describe the expanded utility of this tool for investigating how PTMs influence 
the enzymatic activity of the writers and erasers of these marks. While others have 
previously used array formats for analyzing substrate specificity of histone 
methyltransferases, libraries for these assays were designed primarily for motif mining 
through amino acid substitutions (Dhayalan, Kudithipudi, Rathert, & Jeltsch, 2011; 
Kudithipudi, Dhayalan, Kebede, & Jeltsch, 2012; Kudithipudi, Kusevic, Weirich, & Jeltsch, 
2014; Kudithipudi, Lungu, Rathert, Happel, & Jeltsch, 2014; Rathert, Dhayalan, et al., 2008; 
Rathert, Zhang, Freund, Cheng, & Jeltsch, 2008; Smith, Settles, Hallows, Craven, & Denu, 
2011). Our studies describe a robust high-throughput assay format optimized for both 
substrate specificity profiling and analysis of the impact that PTMs have on both KMT and 
KDM activity. It is now possible to investigate one of the key tenets of the original “histone 
code” hypothesis, that neighboring PTMs on histones impact the function of the enzymes 
that write and erase these marks. Indeed, we found that PTMs adjacent to the target amino 
acid both enhance and abrogate the KMT and KDM activity of both G9a and JMJD2A, 
respectively. Furthermore, we identified several distant PTMs that strongly perturb and 
enhance G9a catalytic function.
While peptide microarrays are a powerful technology for studying the activity of histone-
modifying enzymes, there are several limitations that should be noted. First, not all histone-
modifying enzymes are active on peptide substrates, limiting the enzymes for which this 
platform can be employed. This is an outstanding issue for all peptide-based approaches, and 
an important challenge for the field, as substrate profiling of these enzymes remains 
challenging. Another important consideration when using antibodies as the detection method 
is ensuring the proper peptide diversity is represented in the displayed library. For example, 
the peptide that corresponds to the product of catalysis in the context of neighboring PTMs 
should be represented to accurately control for antibody specificity.
Characterization of the impact that PTMs have on the catalytic activity of histone-modifying 
enzymes will be crucial in understanding the dynamic histone PTM language. It is important 
to note that combined, nearly 80 KMTs and KDMs have been identified. Additionally, the 
methods described above can serve as guidelines for adapting this microarray approach for 
histone-modifying enzymes that catalyze the addition or removal of modifications other than 
lysine methylation. Thus, microarray-based enzyme assays and similar approaches are 
poised to be widely used tools to aid in unraveling how the histone PTM landscape is 
created, maintained, and erased.
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Fig. 1. 
The dynamic regulation of lysine methylation on histone H3. Shown are major sites of 
methylation (me), acetylation (ac), and phosphorylation (p) on the N-terminal tail domain of 
histone H3. Known writers (methyltransferases; KMTs) and erasers (demethylases; KDMs) 
of lysine methylation are clustered by major histone substrate residue(s). Methylation 
products and substrates (mono-, me1; di-, me2; tri-, me3) of KMT and KDM reactions, 
respectively, are listed. Enzyme identification reflects both conventional and generic (Allis et 
al., 2007) nomenclature.
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Fig. 2. 
Optimization of a G9a KMT assay on microarrays. (A) A 48-well optimization array 
partitioned by hydrophobic wax. (B and C) Scanned image of an optimization array assay 
following a 2-h incubation with seven G9a concentrations, a no enzyme control (0), and 
three detection antibodies (H3K9me1, EpiCypher #13-0014; H3K9me2, Abcam #1220; 
H3K9me3, Active Motif #39161), all in duplicate. (D) Print layout of individual arrays 
partitioned on 48-well optimization slides. Each array consists of 24 unique histone peptides 
printed in duplicate. Peptide identifications numbers correspond to those used previously 
(Rothbart et al., 2015). P245 and P177 are H3(1–32) and H3(1–43), respectively. Biotin-4-
Fluorescein (not shown) is printed in the corners of each array as a spotting control and a 
landmark to aid in alignment for data analysis.
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Fig. 3. 
Analysis of G9a histone substrate specificity and the combinatorial PTM influence on KMT 
activity. G9a histone substrate specificity was profiled using the described antibody and 
radioisotopic detection strategies on large-format histone peptide micro-arrays. (A) 
Representative images of arrays detected with an H3K9me2 antibody (Abcam #1220) 
following hybridization in the absence or presence of 1 μM G9a for 2 h (left). White boxes 
demarcate peptides detected by H3K9me2 antibody in the absence of G9a. Image of 
autoradiography film exposed for 1.5 months following a 2-h array assay with 1 μM G9a 
and 5 μCi 3H-SAM (right). For comparison, yellow boxes demarcate peptides detected with 
H3K9me2 antibody in the presence of G9a. (B) Scatter plot (left) and heat map (right) of 
H3K9me2 peptides detected by the above-mentioned H3K9me2 antibody in the absence or 
presence of G9a. Correlation coefficient (r2) was calculated by linear regression analysis 
using GraphPad Prism v6. For heat maps, relative signal intensities are plotted using 
JavaTreeView (Saldanha, 2004) from 0 (white, no binding) to 1 (blue, strong binding). (C) 
Heat maps depicting the effects of combinatorial PTMs on the enzymatic activity of G9a 
from panel (A). Enhanced (1, blue) and occluded (−1, red) effects are depicted. Peptide 
signal intensities are presented relative to H3(1–20) (0, white) following detection with the 
above-mentioned H3K9me2 antibody (left) or autoradiography (right). (D) In-solution 3H-
SAM filter-binding assays monitoring G9a activity as a function of time on the listed histone 
peptide substrates. Data points are presented as counts per minute (cpm), each from three 
independent measurements. (E) In-solution 3H-SAM filter-binding assays monitoring G9a 
activity following a 10-min incubation with the listed histone peptide substrates. Data points 
are presented as cpm relative to an H3(1–20) substrate. Error bars represent ±S.E.M. from 
three independent experiments.
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Fig. 4. 
Analysis of JMJD2A histone substrate specificity and the combinatorial PTM influence on 
KDM activity. (A) Optimization of JMJD2A demethylase activity on H3(1–20)K9me3 
peptides in a 48-well microarray (see Fig. 2A). The indicated orders of H3K9 methylation 
were detected by antibody hybridization (H3K9me1, EpiCypher #13-0014; H3K9me2, 
Active Motif #39239; H3K9me3, Active Motif #39161) following 18 h incubation with the 
indicated concentrations of JMJD2A. Fold change is expressed relative to signal intensity in 
the absence of enzyme. Error bars represent ±S.E.M. (B) Representative images of arrays 
detected with an H3K9me1 antibody (EpiCypher #13-0014) following hybridization in the 
absence or presence of 313 nM JMJD2A for 18 h. White boxes demarcate peptides detected 
by H3K9me1 antibody in the absence of JMJD2A. (C) Scatter plot of all peptides on the 
large array detected with the abovementioned H3K9me1 antibody following hybridization in 
the absence or presence of JMJD2A. Signal intensities are normalized to IgG control spots. 
(D) Bar graphs depicting the effects of combinatorial PTMs on the enzymatic activity of 
JMJD2A from panel (B). Signal intensities from H3K9me1 antibody detection are 
normalized to IgG control spots. Shown are signals for the indicated peptides that also 
contain H3K9me2 (left) or H3K9me3 (right), both in the absence (−) and presence (+) of 
JMJD2A. To control for H3K9me1 antibody specificity in the context of these additional 
PTMs, normalized signal intensities from these peptides that also contain H3K9me1 
(H3K9me1 Ctrl) are plotted as a reference.
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